Equities Analysts Set Expectations for DFTX Q1 Earnings

Definium Therapeutics, Inc. (NASDAQ:DFTX) – Equities researchers at HC Wainwright dropped their Q1 2026 EPS estimates for shares of Definium Therapeutics in a note issued to investors on Monday, March 2nd. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.46) per share for the quarter, down from their previous forecast of ($0.38). HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Definium Therapeutics’ current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Definium Therapeutics’ Q2 2026 earnings at ($0.46) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.46) EPS, FY2026 earnings at ($1.83) EPS, FY2027 earnings at ($1.52) EPS, FY2028 earnings at $0.72 EPS, FY2029 earnings at $3.24 EPS and FY2030 earnings at $5.32 EPS.

Several other research analysts have also recently commented on DFTX. Robert W. Baird set a $37.00 price target on Definium Therapeutics in a research note on Thursday, January 29th. Jefferies Financial Group initiated coverage on Definium Therapeutics in a research report on Thursday, January 29th. They issued a “buy” rating and a $30.00 target price on the stock. Wolfe Research started coverage on Definium Therapeutics in a research note on Monday, February 23rd. They set an “outperform” rating and a $25.00 target price for the company. Needham & Company LLC restated a “buy” rating on shares of Definium Therapeutics in a research note on Monday, January 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a report on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $35.70.

Definium Therapeutics Stock Performance

NASDAQ:DFTX opened at $17.55 on Thursday. The firm has a 50-day moving average of $15.98 and a two-hundred day moving average of $13.02. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.29 and a quick ratio of 6.29. The stock has a market cap of $1.73 billion, a P/E ratio of -8.24 and a beta of 2.56. Definium Therapeutics has a 1-year low of $4.70 and a 1-year high of $18.70.

Insider Buying and Selling

In related news, insider Mark Sullivan sold 11,276 shares of the business’s stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $148,279.40. Following the completion of the transaction, the insider owned 282,576 shares in the company, valued at $3,715,874.40. The trade was a 3.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Robert Barrow sold 25,791 shares of the stock in a transaction on Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $339,151.65. Following the completion of the sale, the chief executive officer directly owned 778,477 shares in the company, valued at $10,236,972.55. This represents a 3.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 42,667 shares of company stock valued at $561,071. Insiders own 2.26% of the company’s stock.

Institutional Trading of Definium Therapeutics

Large investors have recently modified their holdings of the company. Russell Investments Group Ltd. increased its stake in Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares in the last quarter. BIT Capital GmbH acquired a new position in shares of Definium Therapeutics in the third quarter worth about $26,000. CWM LLC increased its position in shares of Definium Therapeutics by 67.4% in the second quarter. CWM LLC now owns 4,459 shares of the company’s stock worth $29,000 after acquiring an additional 1,796 shares in the last quarter. Fifth Third Bancorp increased its position in shares of Definium Therapeutics by 5,593.2% in the third quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock worth $40,000 after acquiring an additional 3,300 shares in the last quarter. Finally, Sound Income Strategies LLC acquired a new stake in shares of Definium Therapeutics during the third quarter valued at approximately $46,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Definium Therapeutics News Roundup

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: HC Wainwright retained a “Buy” rating and a $70 price target and raised FY2028–FY2030 EPS forecasts (FY2028 to $0.72, FY2029 to $3.24, FY2030 to $5.32), supporting sizable long‑term upside expectations. HC Wainwright Forecasts Strong Price Appreciation for Definium Therapeutics (NASDAQ:DFTX) Stock
• Neutral Sentiment: Short‑interest data in the recent report shows 0 shares shorted and a 0.0 days-to-cover figure — likely a reporting anomaly and not indicative of a material short squeeze risk or position change.
• Neutral Sentiment: Trading and technicals: volume is roughly in line with average, the stock sits above its 50‑day and 200‑day moving averages, and remains near its 52‑week high — factors that temper downside but also reflect prior run‑up. Definium Therapeutics (DFTX) MarketBeat Profile
• Negative Sentiment: HC Wainwright lowered near‑term earnings estimates across Q1–Q4 2026 (each quarter to ($0.46) from ($0.38)) and cut FY2026 and FY2027 EPS, signaling weaker near‑term profitability and likely contributing to the stock’s downward pressure today. HC Wainwright Forecasts Strong Price Appreciation for Definium Therapeutics (NASDAQ:DFTX) Stock

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.